ZNTL has 36-month beta value of 1.80. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ZNTL is 63.80M, and currently, short sellers hold a 26.08% ratio of that float. The average trading volume of ZNTL on April 26, 2024 was 824.90K shares.
ZNTL) stock’s latest price update
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)’s stock price has decreased by -6.67 compared to its previous closing price of 11.77. However, the company has seen a -12.40% decrease in its stock price over the last five trading sessions. Seeking Alpha reported 2024-04-12 that Zentalis Pharmaceuticals, Inc. expects final results from phase 1b study, using azenosertib + gemcitabine for the treatment of patients with osteosarcoma, in the 1st half of 2024. In a phase 1 study, using monotherapy azenosertib for 19 patients with platinum resistant or refractory ovarian cancer and uterine serous carcinoma patients, the ORR achieved was 37%. Initiation of a clinical trial using azenosertib for 1st-line maintenance platinum-sensitive ovarian cancer patients expected in 2025; Trial design to be revealed in the 2nd half of 2024.
ZNTL’s Market Performance
Zentalis Pharmaceuticals Inc (ZNTL) has experienced a -12.40% fall in stock performance for the past week, with a -22.04% drop in the past month, and a -15.95% drop in the past quarter. The volatility ratio for the week is 6.98%, and the volatility levels for the past 30 days are at 7.22% for ZNTL. The simple moving average for the last 20 days is -21.85% for ZNTL stock, with a simple moving average of -36.66% for the last 200 days.
Analysts’ Opinion of ZNTL
Many brokerage firms have already submitted their reports for ZNTL stocks, with Wedbush repeating the rating for ZNTL by listing it as a “Neutral.” The predicted price for ZNTL in the upcoming period, according to Wedbush is $12 based on the research report published on November 08, 2023 of the previous year 2023.
Leerink Partners, on the other hand, stated in their research note that they expect to see ZNTL reach a price target of $15. The rating they have provided for ZNTL stocks is “Market Perform” according to the report published on November 07th, 2023.
ZNTL Trading at -21.72% from the 50-Day Moving Average
After a stumble in the market that brought ZNTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.08% of loss for the given period.
Volatility was left at 7.22%, however, over the last 30 days, the volatility rate increased by 6.98%, as shares sank -27.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.43% upper at present.
During the last 5 trading sessions, ZNTL fell by -12.40%, which changed the moving average for the period of 200-days by -59.81% in comparison to the 20-day moving average, which settled at $13.85. In addition, Zentalis Pharmaceuticals Inc saw -27.49% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZNTL starting from Epperly Melissa B, who sale 2,573 shares at the price of $11.44 back on Feb 12 ’24. After this action, Epperly Melissa B, now owns 451,449 shares of Zentalis Pharmaceuticals Inc, valued at $29,435 using the latest closing price.
Gallagher Cam, the President of Zentalis Pharmaceuticals Inc, sale 1,173 shares at $11.44 during a trade that took place back on Feb 12 ’24, which means that Gallagher Cam is holding 643,277 shares at $13,419 based on the most recent closing price.
Stock Fundamentals for ZNTL
The total capital return value is set at -0.61. Equity return is now at value -67.09, with -52.39 for asset returns.
Based on Zentalis Pharmaceuticals Inc (ZNTL), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -4.54. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is 50.33.
Currently, EBITDA for the company is -252.55 million with net debt to EBITDA at -0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.16.
Conclusion
To put it simply, Zentalis Pharmaceuticals Inc (ZNTL) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
